These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17683513)

  • 1. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy.
    Kim WY; Nakata B; Hirakawa K
    Cancer Sci; 2007 Oct; 98(10):1604-8. PubMed ID: 17683513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
    Yamada Y
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():37-41. PubMed ID: 16897970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
    Tsuruoka Y; Kamano T; Kitajima M; Kawai K; Watabe S; Ochiai T; Sakamoto K; Shirasaka T
    Anticancer Drugs; 2006 Apr; 17(4):393-9. PubMed ID: 16549996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
    Yamada Y; Hamaguchi T; Goto M; Muro K; Matsumura Y; Shimada Y; Shirao K; Nagayama S
    Br J Cancer; 2003 Sep; 89(5):816-20. PubMed ID: 12942110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
    Yoshisue K; Kanie S; Nishimura T; Chikamoto J; Nagayama S
    J Pharm Pharmacol; 2009 Dec; 61(12):1643-51. PubMed ID: 19958587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
    Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
    Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
    Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
    Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
    Kochi M; Fujii M; Kanamori N; Kaiga T; Aizaki K; Takahashi T; Takayama T
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):693-701. PubMed ID: 17690883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
    Fujita K; Yamamoto W; Endo S; Endo H; Nagashima F; Ichikawa W; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Kamataki T; Sasaki Y
    Cancer Sci; 2008 May; 99(5):1049-54. PubMed ID: 18380793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postgastrectomy pharmacokinetic changes of S-1 in patients with localized advanced gastric cancer.
    Lim HS; Ryu KW; Lee JH; Kim YW; Ju Choi I; Kim MJ; Park YI; Hwang A; Park SR
    J Clin Pharmacol; 2015 Aug; 55(8):926-35. PubMed ID: 25810324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
    Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
    Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients].
    Matsumoto H; Hirai T; Hirabayashi Y; Murakami H; Higashida M; Kawabe Y; Fuchimoto M; Fujikura H; Hato S; Urakami A; Yamashita K; Tsunoda T
    Gan To Kagaku Ryoho; 2007 Jun; 34(6):869-73. PubMed ID: 17565248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.
    Booka E; Imamura CK; Takeuchi H; Hamamoto Y; Gomi D; Mizukami T; Ichiyama T; Tateishi K; Takahashi T; Kawakubo H; Soejima K; Boku N; Tanigawara Y; Kitagawa Y
    Gastric Cancer; 2016 Jul; 19(3):876-86. PubMed ID: 26304171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of S-1 monotherapy in plasma and in tears for gastric cancer patients.
    Yasui H; Kawakami T; Kashiwagi H; Mori K; Omae K; Kasai J; Yoshisue K; Kawahira M; Tsushima T; Machida N; Fukutomi A; Yamaguchi K
    Int J Clin Oncol; 2019 Jun; 24(6):660-665. PubMed ID: 31011915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics of S-1].
    Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.
    Hirose T; Fujita K; Nishimura K; Ishida H; Yamashita K; Sunakawa Y; Mizuno K; Miwa K; Nagashima F; Tanigawara Y; Adachi M; Sasaki Y
    Oncol Rep; 2010 Aug; 24(2):529-36. PubMed ID: 20596643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism.
    Sasaki E; Tominaga K; Kuwamura H; Watanabe T; Fujiwara Y; Oshitani N; Higuchi K; Arakawa T
    J Gastroenterol; 2007 Oct; 42(10):816-22. PubMed ID: 17940834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.
    Jeung HC; Rha SY; Shin SJ; Ahn JB; Noh SH; Roh JK; Chung HC
    Jpn J Clin Oncol; 2010 Jan; 40(1):29-35. PubMed ID: 19880858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.